Orchid Pharma Q1 FY27 earnings call transcript filed with exchanges

Mgmt Guided Margin ImprovementMgmt Guided Margin PressureOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDF Explain this filing

ORCHPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-6.5%1-day move

₹1039.05

prior close

₹1039.50

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.9-0.9-1.1-1.6-6.5-10.5-6.2-4.0-8.5-9.3-7.3+2.4——

Up moveDown movePending

AI summary

Orchid Pharma filed the transcript of its Q1 FY27 earnings call held Aug 21, 2026. Q1 revenue grew 15 percent year-on-year to INR304 crores, with EBITDA rising to INR25 crores from INR10 crores. Gross margin improved to 33 percent from 30 percent. Numbers are combined post the Dhanuka Laboratories merger effective July 2026. Management expects better regulated market demand in H2 due to winter season. Cefiderocol plant commissioning is targeted by December 2026 and 7-ACA first commercial batch by March 2027. Exblifep volumes grew about 50 percent in Europe.

Likely market impact

Improved Q1 numbers and progress on 7-ACA and Cefiderocol projects are positive, but cephalosporin pricing pressure and competitive intensity remain key concerns.